Jul 06, 2019
Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
Jun 17, 2019
Pfizer to Acquire Array BioPharma
May 29, 2019
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
May 07, 2019
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
Apr 30, 2019
Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019
Mar 05, 2019
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
Feb 21, 2019
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
Feb 05, 2019
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
Jan 29, 2019
Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019
Jan 14, 2019
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
Dec 20, 2018
Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 20, 2018
Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
Nov 06, 2018
Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference
Oct 23, 2018
Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018
Aug 10, 2018
Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors
Aug 07, 2018
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018
Jul 13, 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Jun 23, 2018
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer
Jun 18, 2018
Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer
Jun 04, 2018
Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma